abrocitinib - Profile

What are the generic sources for abrocitinib and what is the scope of patent protection?

Abrocitinib is the generic ingredient in one branded drug marketed by Pfizer and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Abrocitinib has sixty-five patent family members in forty-four countries.

Summary for abrocitinib

International Patents:	65
US Patents:	3
Tradenames:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for abrocitinib

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for abrocitinib

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Paragraph IV (Patent) Challenges for ABROCITINIB

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
CIBINQO	Tablets	abrocitinib	50 mg, 100 mg and 200 mg	213871	3	2026-01-14

US Patents and Regulatory Information for abrocitinib

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	CIBINQO	abrocitinib	TABLET;ORAL	213871-001	Jan 14, 2022		RX	Yes	No
Pfizer	CIBINQO	abrocitinib	TABLET;ORAL	213871-001	Jan 14, 2022		RX	Yes	No			Y	Y
Pfizer	CIBINQO	abrocitinib	TABLET;ORAL	213871-001	Jan 14, 2022		RX	Yes	No			Y	Y
Pfizer	CIBINQO	abrocitinib	TABLET;ORAL	213871-001	Jan 14, 2022		RX	Yes	No

EU/EMA Drug Approvals for abrocitinib

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Pfizer Europe MA EEIG	Cibinqo	abrocitinib	EMEA/H/C/005452Cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.	Authorised	no	no	no	2021-12-09

International Patents for abrocitinib

Country	Patent Number	Title	Estimated Expiration
Argentina	094857	DERIVADOS DE PIRROLO[2,3-D]PIRIMIDINA
Australia	2014220357	Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of Janus- related Kinases (JAK)
Brazil	112015019634	derivados de pirrolo[2,3-d]pirimidina como inibidores de janus kinase (jak)
Canada	2900703	DERIVES DE PYRROLO[2,3-D]PYRIMIDINE EN TANT QU'INHIBITEURS DE JANUS KINASES (JAK) (PYRROLO [2, 3 -D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF JANUS- RELATED KINASES (JAK))

Supplementary Protection Certificates for abrocitinib

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2958921	122022000007	Germany		PRODUCT NAME: ABROCITINIB, ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/21/1593 20211209
2958921	301155	Netherlands		PRODUCT NAME: ABROCITINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: PLGB 00057/1703-1705 20210908
2958921	LUC00261	Luxembourg		PRODUCT NAME: ABROCITINIB, OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/21/1593 20211210
2958921	CA 2022 00003	Denmark		PRODUCT NAME: ABROCITINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/21/1593 20211210

Abrocitinib Investment and Fundamentals Analysis

Last updated: February 5, 2026

What is Abrocitinib and What is Its Market Position?

Abrocitinib is a Janus kinase 1 (JAK1) inhibitor developed by Pfizer. It received FDA approval in January 2022 for treating moderate-to-severe atopic dermatitis in adults. As a targeted therapy, abrocitinib competes with other JAK inhibitors such as Eli Lilly’s baricitinib and AbbVie’s upadacitinib, all approved for similar indications.

The drug’s mechanism involves blocking cytokine signaling pathways that contribute to inflammation in atopic dermatitis. The global atopic dermatitis market is projected to reach $4.8 billion by 2027, growing at a CAGR of approximately 10%, driven by increasing prevalence and unmet medical needs.

What are the Core Investment Drivers?

• Market Penetration: Pfizer's entrenched global distribution channels and marketing capabilities position abrocitinib for rapid uptake in both developed and emerging markets.
• Pricing and Reimbursement: As an innovative biologic alternative, abrocitinib commands premium pricing, supported by its targeted mechanism and efficacy profile.
• Regulatory Landscape: Positive regulatory reviews in multiple jurisdictions, including Japan and the EU, facilitate broader access.
• Pipeline and Expansion: Pfizer is exploring additional indications like alopecia areata and other inflammatory diseases, which can extend market opportunities.
• Competitive Dynamics: The JAK inhibitor class faces increasing competition from biologic therapies, but the oral administration of abrocitinib aligns with patient preferences.

What Are the Revenue and Market Share Projections?

Based on analyst forecasts, Pfizer projects initial sales of approximately $200 million globally in 2022, with estimates rising to over $1 billion within five years. The drug could capture 15-20% of the atopic dermatitis market segment. Competitors like Rinvoq (upadacitinib) currently dominate the JAK space, but abrocitinib’s unique profile allows for differentiation in pricing and positioning.

What Are the Key Financial and Patent Considerations?

• Patent Protection: Pfizer's patents for abrocitinib are primarily valid until 2030-2035, with potential extensions through formulation patents, protecting exclusivity in major markets.
• Development Costs: As a late-stage product, Pfizer's R&D expenditure mainly comprises clinical trial costs, estimated at $300 million through 2024.
• Profitability: Gross margins for Pfizer's specialty drugs typically exceed 70%. Abrocitinib's incremental cost of goods sold (COGS) is projected at 20-25% of sales, supporting high profitability if market penetration is achieved.

What Risks Exist?

• Regulatory Risks: Possible delays or rejections based on safety or efficacy concerns.
• Competitive Risks: The presence of multiple JAK inhibitors, alongside emerging biologic therapies, limits market share potential.
• Pricing and Reimbursement: Payer pushback on high costs could limit access and weaken sales.
• Patent Challenges: Generic or biosimilar entries could threaten exclusivity post-2030.

What Is the Investment Outlook?

The outlook remains cautiously optimistic. Pfizer’s strategic marketing and pipeline expansion support growth, but competition and regulatory uncertainties introduce risk. Abrocitinib's high unmet need in dermatitis positions it as a valuable long-term asset if market assumptions hold.

Key Takeaways

• Abrocitinib is a Pfizer-developed JAK1 inhibitor approved for atopic dermatitis.
• The global atopic dermatitis market is expanding, offering significant growth prospects.
• Revenue estimates project over $1 billion within five years, contingent on market share gain.
• Patent protections extend into the early 2030s, with potential for additional indications.
• Risks include competitive pressure, pricing negotiations, and regulatory developments.

FAQs

1. How does abrocitinib compare to other JAK inhibitors?
Abrocitinib has a shorter time to market and a comparable efficacy profile but faces competition from upadacitinib, which has broader labeling for some inflammatory conditions.

2. What are the main safety concerns?
As with other JAK inhibitors, risks include infections, blood clots, and unusual thromboses, which can influence regulatory and market acceptance.

3. When will sales likely peak?
Sales could peak between 2026 and 2030, depending on market penetration, competition, and approval of new indications.

4. Can patent exclusivity be extended?
Yes, through method-of-use and formulation patents, which Pfizer has actively pursued.

5. What markets are strategic for expansion?
North America and Europe will dominate initial sales, but emerging markets in Asia and Latin America hold significant growth potential.

---

Sources

1. Pfizer. "Abrocitinib (Cibinqo) highlights." February 2022.
2. Market Research Future. "Global Atopic Dermatitis Market Analysis." 2021.
3. FDA. "Abrocitinib Approval Letter," 2022.
4. EvaluatePharma. "2019-2024 Global Pharmaceutical Market Outlook." 2021.
5. PatentScope. "Pfizer’s Patent Portfolio for Abrocitinib." 2022.